STOK Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 19%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Biogen, Inc.'s return on equity of 9.36%.

Stoke Therapeutics, Inc. has a consensus price target of $39.63, signalling upside risk potential of 27.54%. On the other hand Biogen, Inc. has an analysts' consensus of $193.00 which suggests that it could grow by 7.29%. Given that Stoke Therapeutics, Inc. has higher upside potential than Biogen, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Biogen, Inc..

Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.301%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Biogen, Inc. quarterly revenues of $2.5B. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Biogen, Inc.'s net income of $466.5M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 47.08x while Biogen, Inc.'s PE ratio is 16.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.82x versus 2.72x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -259.95%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Insmed, Inc.'s return on equity of -193.23%.

Stoke Therapeutics, Inc. has a consensus price target of $39.63, signalling upside risk potential of 27.54%. On the other hand Insmed, Inc. has an analysts' consensus of $215.10 which suggests that it could grow by 37.12%. Given that Insmed, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Insmed, Inc. is more attractive than Stoke Therapeutics, Inc..

Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.085, suggesting its more volatile than the S&P 500 by 8.523%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Insmed, Inc.'s net income of -$370M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 47.08x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.82x versus 66.76x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Mirum Pharmaceuticals, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of 2.18%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Mirum Pharmaceuticals, Inc.'s return on equity of -16.73%.

Stoke Therapeutics, Inc. has a consensus price target of $39.63, signalling upside risk potential of 27.54%. On the other hand Mirum Pharmaceuticals, Inc. has an analysts' consensus of $109.90 which suggests that it could grow by 6.78%. Given that Stoke Therapeutics, Inc. has higher upside potential than Mirum Pharmaceuticals, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Mirum Pharmaceuticals, Inc..

Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Mirum Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.567%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mirum Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Mirum Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Mirum Pharmaceuticals, Inc. quarterly revenues of $133M. Stoke Therapeutics, Inc.'s net income of -$38.3M is lower than Mirum Pharmaceuticals, Inc.'s net income of $2.9M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 47.08x while Mirum Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.82x versus 11.11x for Mirum Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -360.68% compared to Stoke Therapeutics, Inc.'s net margin of -19.69%. Stoke Therapeutics, Inc.'s return on equity of 13.95% beat Moderna, Inc.'s return on equity of -30.18%.

Stoke Therapeutics, Inc. has a consensus price target of $39.63, signalling upside risk potential of 27.54%. On the other hand Moderna, Inc. has an analysts' consensus of $37.70 which suggests that it could fall by -19.55%. Given that Stoke Therapeutics, Inc. has higher upside potential than Moderna, Inc., analysts believe Stoke Therapeutics, Inc. is more attractive than Moderna, Inc..

Stoke Therapeutics, Inc. has a beta of 1.102, which suggesting that the stock is 10.227% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.991%.

Stoke Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stoke Therapeutics, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Stoke Therapeutics, Inc. quarterly revenues are $10.6M, which are smaller than Moderna, Inc. quarterly revenues of $1B. Stoke Therapeutics, Inc.'s net income of -$38.3M is higher than Moderna, Inc.'s net income of -$200M. Notably, Stoke Therapeutics, Inc.'s price-to-earnings ratio is 47.08x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stoke Therapeutics, Inc. is 8.82x versus 8.13x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.